US GLP-1 telehealth in May 2026 · who's actually routable after the 503B exclusion proposal

The US GLP-1 telehealth market hit a regulatory inflection in early 2026. Three events stacked: enforcement discretion ended for 503A and 503B compounders (February + March 2025), Foundayo (orforglipron) approved as the first oral small-molecule GLP-1 (April 1, 2026), and the FDA formally proposed excluding tirzepatide from the 503B bulks list (April 30, 2026, comment period through June 29). Eli Lilly + Novo Nordisk have been suing the larger compounded-leaning platforms in parallel. The cheap-compounded-supply lane that made $99-$199/month telehealth GLP-1 a viable mass-market product is closing.

This is the routing map for May 2026 across the eight US telehealth platforms in the Panya catalog. Each one scored against the same 11-signal rubric we apply to every vendor.

The three routable options

These three platforms have each made a clean-enough pivot to brand pharmacy that the April 30 proposal doesn't structurally threaten their supply.

Ro (scorecard · 70 · routable) is the most pivot-complete. April 9, 2026 announcement integrated Foundayo (orforglipron) at a $149/mo cash-pay price; Lilly partnership routes Zepbound vials through LillyDirect + Gifthealth; insurance-eligible brand-name path layered on top. No compounded exposure to the April 30 proposal. Insurance Checker tool has helped 2M+ users verify benefits coverage. The cleanest single answer in the cohort.

Calibrate (scorecard · 68 · routable) is the year-long-program option. Brand-only formulary (Wegovy + Zepbound + Foundayo). Insurance-first navigation pushes most commercial-plan members to ~$25/mo branded GLP-1 copays. The differentiator is the structured behavioural program · food + sleep + exercise + emotional-health coaching wrapping the medication. $199/mo program fee on top of medication cost. Slower-burn fit for patients who want a year-long metabolic-health framing rather than pure-Rx-fulfillment.

WeightWatchers Clinic (scorecard · 67 · routable) is the behavioural-program-first option. Acquired Sequence in November 2023 for $132M and went brand-only at integration. Wegovy + Zepbound + oral Wegovy 25mg from early 2026. The Points-system + dietitian + community wrap is what makes adherence stickier than competitors · the Rx is one component of a larger behavioural program. Brand-only since 2023 means no compounded overhang.

If a reader is asking "where do I actually go in May 2026 for GLP-1 weight management telehealth", the answer is one of these three. Pick by fit:

• Ro for cash-pay simplicity + the Foundayo oral path
• Calibrate for insurance-first + structured year-long program
• WW Clinic for behavioural-program scaffolding

The conditional

Found Health (scorecard · 55 · conditional) is the hybrid option. Insurance-first GLP-1 facilitator · covered by 1 in 3 commercial plans, $30 copay typical. For insured patients the path is clean. The compounded fallback channel for uninsured patients is what keeps it conditional rather than routable · that channel narrows under the April 30 proposal. If you have insurance coverage, treat as routable. If you do not, watch how the Q3 2026 final rule lands before relying on Found's compounded path.

The four on hold

These four operators have not (yet) made a clean enough pivot to clear our routing bar in May 2026.

Hims & Hers (scorecard · 48 · hold) is mid-pivot. The September 9, 2025 FDA Warning Letter cited the Hers brand for misleading compounded-semaglutide marketing claims. The February 9, 2026 Novo Nordisk patent-infringement lawsuit alleges 'inauthentic API' in the compounded supply. The March 2026 announced integration with Novo Nordisk brand semaglutide is the right pivot, but execution is mid-flight and legacy compounded supply remains active during the transition window. We will revisit when the brand-pivot completes and the Novo suit resolves.

Mochi Health (scorecard · 38 · hold) is the most exposed front-end in the cohort. 100% compounded model, $99/mo semaglutide and $199/mo tirzepatide, $79/mo membership. Their primary pharmacy partner Aequita was shut down by Washington State in March 2025 for sterile-compounding violations · the relevant testing-discipline gap for compounded injectables. No public brand-pivot announced. The April 30 proposal closes their entire supply channel within months. Hold until either a brand pivot lands or the 503B comment period (closes June 29) produces a different outcome.

Henry Meds (scorecard · 42 · hold) received a March 2026 FDA Warning Letter citing misleading equivalence claims for compounded semaglutide / tirzepatide vs FDA-approved brand and gaps in USP <797> compliance documentation. Active class-action lawsuit in a 2026 settlement window. Compounded model intact through May 2026 despite the letter and lawsuit. The 503B exclusion final rule (Q3 2026) likely closes core supply absent a brand pivot.

Eden (scorecard · 48 · hold) is the hybrid + vertical-integration option. Acquired Contigo Compounding (now Eden Pharmacy, 503A) in August 2025 to vertically integrate. The vertical integration partially insulates against the partner-pharmacy disruption pattern that hit Mochi · direct QC control beats the Aequita-style failure mode. But 503A standards remain below 503B, and the broader compounded-GLP-1 sunset still applies. 127k+ members reported. "Same price at every dose" pricing ($249/$349 compounded, $1,399-$1,695 brand) is a real differentiator on the brand side. Hold pending brand-pivot announcement or rule outcome.

What to actually look for if you're shopping

Three filters cut through the noise in May 2026:

1. Brand-only formulary, or close to it. The April 30 proposal closes the mass-compounded path. A platform that lists Wegovy, Zepbound, Mounjaro, Foundayo as the medication options is not exposed. A platform whose front-page price is $99-$199/month is almost certainly compounded · ask before committing. 2. Insurance navigation as a core feature, not an afterthought. $25-$30/month branded GLP-1 copays are real for most commercial-plan members. A platform that runs a free insurance check before signup is doing the work that makes brand-pharmacy routing viable. A platform that pushes you to cash-pay compounded without checking your coverage is leaving real value on the table. 3. Pivot announcements on the public record. Hims (March 2026 Novo integration) and Ro (April 2026 Foundayo + Lilly partnership) are the model. Operators that have not made a public brand-pivot announcement by Q3 2026 are likely in trouble when the final rule lands · the regulatory discount window is small.

What we cover today

For readers who want the routable answer: /vendor/ro-telehealth, /vendor/calibrate-telehealth, /vendor/ww-clinic-telehealth. All three score above 65 against the Panya 11-signal rubric and have made the brand pivot.

For the regulatory event coverage: /blog/peptide-pulse-may-2026 walks through the April 30 503B-exclusion proposal alongside the other May 2026 events (Foundayo approval, oral Wegovy launch, RFK Category 2 reclassification, counterfeit-enforcement spike).

For the methodology behind every routing call: /blog/11-signals-vendor-rubric.

We will revisit this map after the June 29 comment period closes and the FDA acts on the final rule. Multiple operators on the hold list have until then to announce brand pivots; the ones that do will move toward conditional or routable.